Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-99
SponsorUniversity Hospital, Toulouse
About this trial
The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example),
Patients with atypical presentations of documented or probable systemic autoimmune diseases,
Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.).
Disqualifiers
Known anemia and hemoglobin <10 g / dl
Patients under protective supervision (guardianship, curators)
Pregnant or breastfeeding woman
Trial population
Patients with autoimmune diseases
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Blood sampling
Biological/VaccineBlood will be taken in larger quantity.
Treatment groups
3,000 Participants
are divided into 1 treatment groupGroup A: patients suffering from autoimmune disease1 intervention
Trial outcomes
Primary outcomes
1
Constitution of a collection of biological samples and clinical-biological data from patients with autoimmune diseases
Prospective collection of all available biological samples and clinical data collected during the normal clinical care
Time frame
through study completion, an average of 1 yearSecondary outcomes
1
Identification and / or validation of new biomarkers for diagnostic and / or prognostic purposes
Use of immune cells and / or biological liquids obtained from patients for cohort studies with new methods of screening (microarray, flow cytometry)
Time frame
through study completion, an average of 1 year2
Identification and / or validation of new predictive biomarkers of relapse and / or response to treatment
Use of immune cells and / or biological liquids obtained from patients for cohort studies with new methods of screening (microarray, flow cytometry)
Time frame
through study completion, an average of 1 year3
Identification of specificities in these patients in order to improve the diagnosis, treatment decisions and / or the pathophysiological understanding of these diseases
Use of immune cells and / or biological samples for transcriptomic and / or proteomic studies, or in order to be used in experimental animal models
Time frame
through study completion, an average of 1 year4
Identification of the determinants of immune reconstitution after cell therapy
Exploring blood cell populations before and after cell therapy with flow cytometry
Time frame
through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov